Display options
Cite
Utke Rank C, Weis Bjerrum O, Larsen TS, et al. Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma. 2015;57(2):348-354doi: 10.3109/10428194.2015.1049171.
Utke Rank, C., Weis Bjerrum, O., Larsen, T. S., Kjær, L., de Stricker, K., Riley, C. H., & Hasselbalch, H. C. (2016). Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leukemia & lymphoma, 57(2), 348-354. https://doi.org/10.3109/10428194.2015.1049171
Utke Rank, Cecilie, et al. "Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera." Leukemia & lymphoma vol. 57,2 (2016): 348-354. doi: https://doi.org/10.3109/10428194.2015.1049171
Utke Rank C, Weis Bjerrum O, Larsen TS, Kjær L, de Stricker K, Riley CH, Hasselbalch HC. Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma. 2016 Feb;57(2):348-354. doi: 10.3109/10428194.2015.1049171. Epub 2015 Jun 18. PMID: 25956046.
Copy Download .nbib Format: NLM
Share it on

Leuk Lymphoma. 2016 Feb;57(2):348-354. doi: 10.3109/10428194.2015.1049171. Epub 2015 Jun 18.

Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera.

Leukemia & lymphoma

Cecilie Utke Rank, Ole Weis Bjerrum, Thomas Stauffer Larsen, Lasse Kjær, Karin de Stricker, Caroline Hasselbalch Riley, Hans Carl Hasselbalch

Affiliations

  1. a Department of Hematology , Roskilde Hospital, University of Copenhagen , Denmark.
  2. b Department of Hematology , Rigshospitalet, University of Copenhagen , Denmark.
  3. c Department of Hematology X , Odense University Hospital , Denmark.
  4. d Department of Pathology , Odense University Hospital , Denmark.
  5. e Department of Hematology , Herlev Hospital, University of Copenhagen , Denmark.

PMID: 25956046 DOI: 10.3109/10428194.2015.1049171

Abstract

Essential thrombocythemia (ET) and polycythemia vera (PV) are Philadelphia chromosome-negative chronic myeloproliferative neoplasms (MPNs) characterized by the JAK2 V617F mutation, which can be found in more than 98% of PV patients and in ∼ 50% of ET patients. Assessment of the JAK2 V617F allele burden by a highly sensitive quantitative PCR (qPCR) assay appears to be a useful tool for monitoring minimal residual disease (MRD) and evaluating treatment efficacy. This report expands and substantiates existing data, showing that IFN-alpha2 is a highly potent immunomodulating agent capable of inducing MRD with low-burden JAK2 V617F, major molecular response (MMR), complete hematological remission (CHR) and complete histomorphological normalization of the bone marrow in a sub-set of patients with ET and PV after long-term treatment (≥ 3.5 years). Furthermore, long-lasting hematological, molecular and histomorphological remissions are sustained after discontinuation of IFN-alpha2 for up to ∼ 5-6 years.

Keywords: Interferon-alpha2; JAK2 V617F; MPNs; essential thrombocythemia; minimal residual disease; polycythemia vera

Publication Types